MTAP and central nervous system cancer: According to the stratified analysis based on different grades of glioma, MTAP expression loss in the high-grade glioma subgroup was almost two-fold greater than in the lower-grade glioma subgroup, although there was no association between MTAP expression and clinicopathological features of patients such as gender and age.